Abstract

The existing information supports the use of this material as described in this safety assessment. Phenylethyl anthranilate was evaluated for genotoxicity, repeated dose toxicity, developmental and reproductive toxicity, local respiratory toxicity, phototoxicity/photoallergenicity, skin sensitization, and environmental safety. Data from phenylethyl anthranilate and the read-across analog cinnamyl anthranilate (CAS # 87-29-6) show that phenylethyl anthranilate is not expected to be genotoxic. The skin sensitization endpoint was completed using the DST for non-reactive materials (900 μg/cm2); exposure is below the DST. The reproductive and local respiratory toxicity endpoints were evaluated using the TTC for a Cramer Class II material, and the exposure to phenylethyl anthranilate is below the TTC (0.009 mg/kg/day and 0.47 mg/day, respectively). Data on read-across analogs phenethyl alcohol (CAS # 60-12-8) and anthranilic acid (CAS # 118-92-3) provide a calculated MOE >100 for the repeated dose and developmental toxicity endpoints. The phototoxicity/photoallergenicity endpoints were evaluated based on UV spectra; phenylethyl anthranilate is not expected to be phototoxic/photoallergenic. The environmental endpoints were evaluated; phenylethyl anthranilate was found not to be PBT as per the IFRA Environmental Standards, and its risk quotients, based on its current volume of use in Europe and North America (i.e., PEC/PNEC), are <1.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.